Novo Nordisk Crushes Q1 Forecasts—But Slashes 2025 Outlook Anyway

Despite record-breaking Q1 earnings from Wegovy and Ozempic sales, Novo Nordisk mysteriously slashes its 2025 outlook. What’s really going on?

Palantir Surges, Crushes Earnings—Then Craters: What Spooked Investors?

Despite crushing earnings and 340% returns, Palantir’s stock nosedived 20% in a puzzling market reaction. What made investors run scared?

Why Super Micro’s Surprising Earnings Forecast Could Leave Unity and Altera Investors Reeling

Super Micro’s brutal $1.4B revenue cut sends shockwaves through tech stocks. Will Unity and Altera investors survive this market-rattling blow?

Why Coca-Cola’s Earnings Reveal More Than Just Profits This Quarter

Beyond profits and margins, Coca-Cola’s earnings mask a stunning global shift. Market powers are changing in ways nobody saw coming.

Why Jamie Dimon Thinks S&P 500 Earnings Are About to Disappoint Investors

Wall Street’s optimistic earnings predictions clash with Jamie Dimon’s grim warning of a potential 5% drop. Market forces are telling a different story.